PathAI has developed an artificial intelligence-powered research platform designed to enhance the precision and efficiency of cancer diagnosis and therapy. The platform utilizes machine and deep learning methods to analyze large aggregated datasets, which allows for the identification of cancer cells individually. This, in turn, enables pathologists to diagnose cancer patients with speed and accuracy.

Investors Include:

Waikit Lau, Camford Capital, Merck Global Health Innovation Fund, Quest Diagnostics, Refactor Capital, DHVC, Mike Volpe, Innospark Ventures, General Catalyst, Pillar VC, Nimble Partners, Tiger Global Management, Ad Super, 8VC, Polaris Partners, Biospring Partners, Bristol-Myers Squibb, General Atlantic, D1 Capital Partners, KdT Ventures, Labcorp Venture Fund, HighSage Ventures, Zal Bilimoria, Fairhaven Capital Partners, Koch Disruptive Technologies.

Collective explained in 2 minutes

Learn how Collective's solutions enable you to manage your risk and maximize your wealth

Learn more

Our available services for this company

Lifetime IncomeCharitable Remainder Trust

Tax SavingsDonor Advised Fund